

Benedict-Tilman Berger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3982589/publications.pdf>

Version: 2024-02-01

32
papers

805
citations

567281

15
h-index

552781

26
g-index

36
all docs

36
docs citations

36
times ranked

1028
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. <i>Cell Chemical Biology</i> , 2018, 25, 206-214.e11.	5.2	197
2	Binding Kinetics Survey of the Drugged Kinome. <i>Journal of the American Chemical Society</i> , 2018, 140, 15774-15782.	13.7	57
3	SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2830-2836.	6.4	56
4	Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-d]pyrrolo[2,3-b]pyridine Scaffold. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5350-5366.	6.4	46
5	Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 1062-1066.	13.8	38
6	Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. <i>Cell Chemical Biology</i> , 2021, 28, 686-698.e7.	5.2	36
7	Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 147, 2847-2861.	5.1	34
8	Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. <i>Angewandte Chemie</i> , 2019, 131, 1074-1078.	2.0	32
9	Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	30
10	Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. <i>Oncotarget</i> , 2020, 11, 535-549.	1.8	29
11	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8142-8160.	6.4	28
12	Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112770.	5.5	27
13	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 20178-20183.	13.8	23
14	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the Ephrin Family. <i>ChemMedChem</i> , 2018, 13, 1629-1633.	3.2	20
15	Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10757-10782.	6.4	18
16	A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5. <i>ACS Chemical Biology</i> , 2020, 15, 862-870.	3.4	15
17	Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38 MAP Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7347-7354.	6.4	14
18	Design of a Two-in-One Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1370-1383.	6.4	13

#	ARTICLE	IF	CITATIONS
19	Selective targeting of the I \pm C and DFG-out pocket in p38 MAPK. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112721.	5.5	12
20	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113299.	5.5	12
21	Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5- <i>c</i>]pyrimidine-Based Macrocycles. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 7799-7817.	6.4	11
22	Novel, highly potent PROTACs targeting AURORA-A kinase. <i>Current Research in Chemical Biology</i> , 2022, 2, 100032.	2.9	9
23	Conformational plasticity of the ULK3 kinase domain. <i>Biochemical Journal</i> , 2021, 478, 2811-2823.	3.7	8
24	Single tracer-based protocol for broad-spectrum kinase profiling in live cells with NanoBRET. <i>STAR Protocols</i> , 2021, 2, 100822.	1.2	8
25	Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13259-13278.	6.4	6
26	A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	6
27	Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13451-13474.	6.4	4
28	Design and Development of a Chemical Probe for Pseudokinase Ca ²⁺ /calmodulin-Dependent Ser/Thr Kinase. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14358-14376.	6.4	3
29	Aurora Kinase A Is Involved in Controlling the Localization of Aquaporin-2 in Renal Principal Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 763.	4.1	3
30	Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. <i>Angewandte Chemie</i> , 2021, 133, 20340-20345.	2.0	2
31	Structure-Kinetic-Relationship Reveals the Mechanism of Selectivity of FAK Inhibitors Over PYK2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
32	Resistance to kinase inhibition through shortened target engagement. <i>Molecular and Cellular Oncology</i> , 2022, 9, 2029999.	0.7	1